EFFECTS OF GROWTH-HORMONE THERAPY IN PREPUBERTAL CHILDREN WITH SHORT STATURE SECONDARY TO INTRAUTERINE GROWTH-RETARDATION

A total of 130 short children were included in a French multicentre study and randomized between a control group (group A) and two groups treated with daily subcutaneous injections of GH at doses of 0.7 IU/kg/week (group B) and 1.4 IU/kg/week (group C) for 2 years. Height velocity was significantly increased (p < 0.0005) in groups B and C, with a greater increase in group C than in group B (p < 0.001). The benefit after 2 years compared with controls was 4.3 cm in group B and 5.9 cm in group C. The rate of bone maturation was not affected by GH therapy. These results led to the conclusion that 2 years of treatment with GH improves final height prognosis in children with short stature secondary to IUGR, and that this effect is dose dependent. The effect on final height has still to be demonstrated.